Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Kobe University Hospital Clinical & Translational Research Center, Kobe, Japan.
BMC Cardiovasc Disord. 2021 Feb 15;21(1):92. doi: 10.1186/s12872-021-01902-0.
The impact of reduction in glycemic excursion on coronary plaques remains unknown. This study aimed to elucidate whether a dipeptidyl peptidase 4 inhibitor could reduce the glycemic excursion and stabilize the coronary plaques compared with conventional management in coronary artery disease (CAD) patients with impaired glucose tolerance (IGT).
This was a multicenter, randomized controlled trial including CAD patients with IGT under lipid-lowering therapy receiving either vildagliptin (50 mg once a day) or no medication (control group) regarding glycemic treatment. The primary endpoint was changes in the minimum fibrous cap thickness and lipid arc in non-significant native coronary plaques detected by optical coherence tomography at 6 months after intervention. Glycemic variability expressed as the mean amplitude of glycemic excursion (MAGE) measured with a continuous glucose monitoring system was evaluated before and 6 months after intervention.
A total of 20 participants with 47 lesions were allocated to either the vildagliptin group (10 participants, 22 lesions) or the control group (10 participants, 25 lesions). The adjusted difference of mean changes between the groups was - 18.8 mg/dl (95% confidence interval, - 30.8 to - 6.8) (p = 0.0064) for the MAGE (vildagliptin, - 20.1 ± 18.0 mg/dl vs. control, 2.6 ± 12.7 mg/dl), - 22.8° (- 40.6° to - 5.1°) (p = 0.0012) for the mean lipid arc (vildagliptin, - 9.0° ± 25.5° vs. control, 15.8° ± 16.8°), and 42.7 μm (15.3 to 70.1 μm) (p = 0.0022) for the minimum fibrous cap thickness (vildagliptin, 35.7 ± 50.8 μm vs. control, - 15.1 ± 25.2 μm).
Vildagliptin could reduce the MAGE at 6 months and may be associated with the decreased lipid arc and increased minimum FCT of the coronary plaques in CAD patients with IGT as compared with the control group. These findings may represent its potential stabilization effect on coronary plaques, which are characteristic in this patient subset. Trial registration Registered in the UMIN clinical trial registry (UMIN000008620), Name of the registry: VOGUE trial, Date of registration: Aug 6, 2012, URL: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000010058.
降低血糖波动对冠状动脉斑块的影响尚不清楚。本研究旨在探讨与常规治疗相比,二肽基肽酶 4 抑制剂(DPP-4i)是否能降低血糖波动,并稳定冠状动脉粥样硬化斑块,研究对象为患有糖耐量受损(IGT)的冠心病(CAD)患者。
这是一项多中心、随机对照试验,包括 20 名在降脂治疗下接受维格列汀(50mg,每天一次)或不接受药物治疗(对照组)的 IGT CAD 患者。主要终点是 6 个月后光学相干断层扫描(OCT)检测到非显著原位冠状动脉斑块的最小纤维帽厚度和脂质弧的变化。使用连续血糖监测系统评估干预前后血糖变异性,用平均血糖波动幅度(MAGE)表示。
共有 20 名参与者(47 处病变)被分配到维格列汀组(10 名参与者,22 处病变)或对照组(10 名参与者,25 处病变)。两组间平均变化的调整差异为 MAGE(维格列汀,-18.8mg/dl;95%置信区间,-30.8 至-6.8)(p=0.0064);平均脂质弧(维格列汀,-22.8°;95%置信区间,-40.6 至-5.1)(p=0.0012);最小纤维帽厚度(维格列汀,42.7μm;95%置信区间,15.3 至 70.1μm)(p=0.0022)。
与对照组相比,维格列汀可降低 6 个月时的 MAGE,且可能与 IGT CAD 患者冠状动脉斑块的脂质弧减少和最小纤维帽厚度增加有关。这些发现可能代表其对冠状动脉斑块的潜在稳定作用,这在该患者亚组中是特征性的。
在 UMIN 临床试验注册中心注册(UMIN000008620),注册名称:VOGUE 试验,注册日期:2012 年 8 月 6 日,网址:https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000010058。